StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report released on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Price Performance
Shares of BLPH opened at $0.01 on Friday. The firm has a market capitalization of $146,796.00, a PE ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.02. The company’s fifty day moving average price is $0.02 and its 200-day moving average price is $0.03.
Bellerophon Therapeutics Dividend Announcement
The business also recently disclosed a dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 20th were issued a dividend of $0.019 per share. This represents a dividend yield of 117.8%. The ex-dividend date was Thursday, December 19th.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Articles
- Five stocks we like better than Bellerophon Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- SAP’s Strong Momentum: A Bullish Setup for Investors
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- The 3 Best Blue-Chip Stocks to Buy Now
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
